DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of insulin and can control the blood sugar level if DPP IV is inhibited in our body. Moreover, DPP IV inhibitors restrict the formation of glucagon, a hormone that increases blood glucose level and thereby control the glucose levels in the body. DPP IV inhibitors are widely utilized as a treatment for type 2 diabetes. Sitagliptin, vildagliptin, saxagliptin and linagliptin are included in the drug class DPP IV. Nasopharyngitis, headache, nausea and hypersensitivity are some of the adverse effects due to the utilization of DPP IV.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/5453
Increasing prevalence of type 2 diabetes is a major public health concern worldwide. National Centre for Biotechnology Information in 2011 stated that in the U.S. more than 8% of the total population is diagnosed with diabetes. Diabetes is associated with a number of complications that includes cardiovascular disease, nephropathy, retinopathy, and neuropathy. Thus, the above mentioned factors derives the global DPP IV inhibitors market. However, the cost for DPP IV inhibitors is very high that might hinder the global DPP IV inhibitors market.
Geographically, North America and Europe dominates the global market for DPP IV inhibitors due to high prevalence rate and rising awareness among people about the DPP IV inhibitors. Asia – Pacific is considered as a fastest growing market due to increasing obese population.
To View TOC of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/toc/5453
Various key players contributing to the global DPP IV inhibitors market comprises Arisaph Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited and Novartis AG.
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Persistence Market Research Pvt. Ltd
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353